Pomalidomide for Myelofibrosis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 22, 2009

Primary Completion Date

May 22, 2018

Study Completion Date

May 22, 2018

Conditions
Polycythemia VeraThrombocythemia
Interventions
DRUG

CC-4047

0.5 mg capsules daily by mouth day 1 through day 28.

DRUG

Prednisone

30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.

DRUG

CC-4047

3.0 mg capsules daily by mouth day 1 through 21.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER